Who is sponsoring NCT04737655?

NCT04737655 is sponsored by PARZIBUT Gilles.

What condition does NCT04737655 study?

NCT04737655 studies COPD Exacerbation.

Is NCT04737655 still recruiting?

NCT04737655 is currently status unknown. Last updated 4 February 2021.

Last reviewed 2021-02-04 · How we verify

NCT04737655: TRIMICU

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-inferiority Evaluation of Trimbow in Critically Ill Patients Admitted in ICU Compared to Standard of Care

Status unknown Phase 4 Last updated 4 February 2021

What this trial tests

Phase 4 trial testing TRIMBOW® pressurised inhalation solution: Beclometasone dipropionate / formoterol fumarate /glycopyrronium 87/5/9 µg per inhalation in COPD Exacerbation in 200 participants. Status unknown.

Timeline

15 February 2021

Primary endpoint
15 February 2023

15 May 2023

Quick facts

Lead sponsor	PARZIBUT Gilles
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	200
Start date	15 February 2021
Primary completion	15 February 2023
Estimated completion	15 May 2023

Drugs / interventions tested

TRIMBOW® pressurised inhalation solution: Beclometasone dipropionate / formoterol fumarate /glycopyrronium 87/5/9 µg per inhalation

Conditions studied

COPD Exacerbation — all drugs for COPD Exacerbation →

Sponsor

PARZIBUT Gilles

Who can join

18 and older, any sex, with COPD Exacerbation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objective: To evaluate non-inferiority of Trimbow, an approved therapy for treatment of severe COPD, in ICU compared to the standard of care which is based on the same therapeutic approach. Study location: CHU Sart-Tilman, 4000 Liège, Belgium Study duration: 2 years Type : Interventional Methodology: Prospective clinical trial Number of patients: 200 (randomized 1:1) Main Inclusion criteria : * Maintenance therapy (LAMA or LABA) for COPD * Age \>18 * Admission for AE of COPD * Signed Inform consent * Admitted in ICU \>24h

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for COPD Exacerbation

Currently open trials in the same condition.

NCT07351929 — Emotional-distress-based Integrated Care Programme in Patients With an Acute Exacerbation of COPD · NA · recruiting
NCT05703919 — Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease · Phase 4 · recruiting
NCT06347536 — Supported Rescue Packs Post-discharge in Chronic Obstructive Pulmonary Disease · Phase 3 · recruiting
NCT06691399 — Role of Oral Care in Prevention of Nosocomial Pneumonia Among COPD Patients · NA · recruiting
NCT05958563 — Impact of Continuous Positive Airway Pressure on the Occurrence of Acute Exacerbations of COPD in Patients With COPD-OSA · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04737655 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PARZIBUT Gilles
Last refreshed: 4 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04737655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing